Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency
Jorge Eduardo Toblli, MD, PhD*,
Alejandra Lombraña, MD,
Patricio Duarte, MD and
Federico Di Gennaro, MD
Hospital Alemán, Buenos Aires, Argentina.
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Hemoglobin Concentration, TSAT, and Creatinine Clearance Throughout the Study
(A) Note that by the third month, there was a significant difference between the groups in hemoglobin level. (B) There was a significant difference in transferrin saturation (TSAT) by the third month. (C) There was a significant difference in creatinine clearance by the third month between the groups.
|
|
View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 NT-proBNP, CRP, and LVEF Evaluated in Both Groups Throughout the Study
(A) NT-pro-brain natriuretic peptide (NT-proBNP); (B) C-reactive protein (CRP); and (C) left ventricular ejection fraction (LVEF) evaluated by echocardiogram in both groups.
|
|
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Relationship Between NT-proBNP and Hemoglobin Level in Both Groups
A significant (p < 0.01) negative correlation between these 2 variables was seen in both groups at baseline (A), although only in group A at the end of the study (B). NT-proBNP = NT-pro brain natriuretic peptide.
|
|
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Relationship Between CRP and Hemoglobin Level in Both Groups
A significant (p < 0.01) negative correlation between these 2 variables in both groups was seen initially (A) and at the end of the study (B). CRP = C-reactive protein.
|
|
|
